1xbet.com

Otsuka Pharmaceutical Co., Ltd. (Otsuka) hereby announces that Otsuka has obtained a favorable decisi1xbet.com in a patent infringement acti1xbet.com against Daicel Corporati1xbet.com (hereinafter "Daicel") and Advanced Medical Care Inc. (hereinafter "AMC").

As announced in the news release dated February 10, 2022, entitled 'Favorable Judgment 1xbet.com Lawsuit 1xbet.com Patent Right Held in Relati1xbet.com to Otsuka Pharmaceutical Foods C1xbet.comtaining Equol', Otsuka obtained a favorable judgment from the Intellectual Property High Court 1xbet.com February 9, 2022 in a patent infringement lawsuit against Daicel and AMC. In resp1xbet.comse to this judgment, Daicel and AMC filed a final appeal and a petiti1xbet.com for acceptance of final appeal with the Supreme Court, but these have both been dismissed by the Supreme Court.

With respect to Otsuka's patent right for Equol-c1xbet.comtaining foods (Patent Registrati1xbet.com No. 6275313; Title of Inventi1xbet.com: Equol-c1xbet.comtaining extract and method for producing the same, equol extracti1xbet.com method, and food c1xbet.comtaining equol; hereinafter the "Patent Right"), Otsuka filed a patent infringement acti1xbet.com arguing that Daicel's act of manufacturing and selling "Flavocell EQ-5", and AMC's act of manufacturing and selling "Equol + Lactobi1xbet.comic Acid" using "Flavocell EQ-5" as a raw material infringed their patent.

In this case, although the Tokyo District Court, the court of first instance, rendered a judgment dismissing Otsuka's claims 1xbet.com September 17, 2020, the Intellectual Property High Court, the court of sec1xbet.comd instance, overturned the judgment of the first instance and ruled in favor of Otsuka(*1) 1xbet.com February 9, 2022. The Supreme Court, the court of final appellate instance, dismissed the final appeal and refused to hear the case in its decisi1xbet.coms dated November 11, 2022, and the decisi1xbet.com of the Intellectual Property High Court, which found that a patent infringement had occurred and granted injuncti1xbet.coms against the infringing parties, has thereby become final and binding (*2).

Thus, Daicel is prohibited from manufacturing and selling "Flavocell EQ-5", and AMC is prohibited from manufacturing and selling "Equol + Lactobi1xbet.comic Acid" using "Flavocell EQ-5" as a raw material.

Otsuka has filed multiple patent infringement acti1xbet.coms seeking damages 1xbet.com the ground of infringement of the Patent Right by "Flavocell EQ-5" and supplement products using Flavocell EQ-5, which are now pending before the Tokyo District Court.
Otsuka will c1xbet.comtinue to vigorously defend and protect its inventi1xbet.coms in relevant fields of technology, and provide safeand high-quality products and informati1xbet.com to support people's health based 1xbet.com scientific evidence.